title: Biological mechanisms underlying the clinical effects of mifepristone (RU 486) on the endometrium.
abstract: The abortifacient and menstrual effects of the potent antiprogestin, RU 486 (mifepriston) are associated with both endometrial hemorrhage and extracellular matrix (ECM) degradation. Such processes reflect reduced perivascular decidual cell hemostatic and increased ECM-degrading protease activity. In this review, we summarize the effects of RU 486 on different proteases involved in these processes and expressed by in vitro decidualized endometrium stromal cells. The expression of tissue factor (TF), the primary initiator of hemostasis; urokinase-type plasminogen activator (uPA); tissue-type plasminogen activator (tPA); plasminogen activator inhibitor-1 (PAI-1) as well as the potent matrix metalloprotease, MMP-3 was assessed. These endpoints of decidualization are regulated by progesterone. It was observed, that RU 486 blocks and reverses progestin-enhanced stromal cell TF protein and mRNA expression and PAI-1 protein and mRNA expression, whereas blocks and reverses progestin-inhibited stromal cell uPA, tPA and MMP-3 protein and mRNA expression. These coordinate enhancement of plasminogen activator and MMP-3 expression promotes proteolysis of the decidual ECM, which leads to endometrial sloughing during menstruation. Moreover, destabilization of endometrial microvessels resulting from degradation of their surrounding ECM is consistent with the heavy bleeding after RU 486 administration. On the other hand, with blocking the expression of TF and PAI-1, RU 486 creates a haemorrhagic and fibrinolytic milieu around the endometrial vessels, suggesting a mechanism for RU 486-induced endometrial hemorrhage. The steroid antagonist RU 486 (mifepristone) causes menstrual bleeding when given during the luteal phase of the menstrual cycle (1) and induces abortion in 64-85% of pregnant patients when administered before the 50. postmenstrual days (2, 3). These clinical actions are thought to reflect the antiprogestational effects of RU 486. Pathologic studies showed, that the effects of RU 486 on primate and human luteal phase endometrium include reduced stromal edema, increased venular diameter. Erythrocyte and leukocyte diapedesis, focal hemorrhage, degeneration of the stromal extracellular matrix, and eventual disruption of the superficial layer of the endometrium (4, 5). This antihormone acts at the receptor level and possibly also at the postreceptor level(s) (6). The most important mechanism of action is to compete with progesterone at the level of their respective binding site in the ligand binding domain of the progesterone receptors. The binding of RU 486 to the receptor leads to conformational changes in the DNA-binding site of the progesterone-receptor (7). As a consequnce of these changes, the interaction between the receptor and the progesterone-response elements in the promoter region of progesterone-responsive genes is altered (7). The menorrhagic and abortifacient properties of RU 486 are associated with the induction of endometrial hemorrhage. The physiological mechanisms by which human endometrium permits menstrual hemorrhage in the absence of pregnancy yet maintains hemostasis during endovascular trophoblast invasion (avoiding early abortion) has been investigated in our laboratory by evaluating endometrial expression of different proteins that play role in the process of hemostasis. Besides the endometrial haemostasis, we also examined the proteolytic processes leading extracellular matrix (ECM) degradation, which is also an integral part of menstruation. In this review we sought to summarize the biological mechanisms underlying the clinical effects of RU 486 on endometrial haemorrhage/haemostasis and on ECM degradation.
authors.affiliation: 1st Department of Obstetrics and Gynecology Semmelweis University, Budapest and Department of Obstetrics and Gynecology, New York University Medical Center, New York, USA.
authors.forename: C
authors.initials: C
authors.lastname: Papp
authors.forename: F
authors.initials: F
authors.lastname: Schatz
authors.forename: G
authors.initials: G
authors.lastname: Krikun
authors.forename: V
authors.initials: V
authors.lastname: Hausknecht
authors.forename: C J
authors.initials: CJ
authors.lastname: Lockwood
mesh_terms: D000021:Abortifacient Agents, Steroidal / Q000494:pharmacology; D003280:Contraceptives, Oral, Synthetic / Q000494:pharmacology; D004717:Endometrium / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism*; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology; D006801:Humans; D008186:Luteolytic Agents / Q000494:pharmacology; D008600:Menstruation-Inducing Agents / Q000494:pharmacology; D015735:Mifepristone / Q000494:pharmacology*; D011247:Pregnancy
chemical_list: D000021:Abortifacient Agents, Steroidal; D003280:Contraceptives, Oral, Synthetic; D006727:Hormone Antagonists; D008186:Luteolytic Agents; D008600:Menstruation-Inducing Agents; D015735:Mifepristone